Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | LONRF3 | Human | (+)-schisandrin B | multiple interactions | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of LONRF3 mRNA] | CTD | PMID:31150632 | LONRF3 | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of LONRF3 mRNA | CTD | PMID:23019147 and PMID:31614463 | LONRF3 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of LONRF3 mRNA | CTD | PMID:19465110 | LONRF3 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Fenretinide results in increased expression of LONRF3 mRNA | CTD | PMID:28973697 | LONRF3 | Human | 6-propyl-2-thiouracil | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Propylthiouracil results in increased expression of LONRF3 mRNA | CTD | PMID:25825206 | LONRF3 | Human | acrylamide | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Acrylamide results in decreased expression of LONRF3 mRNA | CTD | PMID:30807115 | LONRF3 | Human | aflatoxin B1 | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of LONRF3 mRNA | CTD | PMID:19770486 | LONRF3 | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of LONRF3 mRNA | CTD | PMID:27153756 | LONRF3 | Human | alpha-Zearalanol | multiple interactions | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of LONRF3 mRNA | CTD | PMID:35163327 | LONRF3 | Human | amphetamine | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Amphetamine results in increased expression of LONRF3 mRNA | CTD | PMID:30779732 | LONRF3 | Human | aristolochic acid A | increases expression | EXP | | 6480464 | aristolochic acid I results in increased expression of LONRF3 mRNA | CTD | PMID:33212167 | LONRF3 | Human | arsenite(3-) | increases expression | EXP | | 6480464 | arsenite results in increased expression of LONRF3 mRNA | CTD | PMID:23974009 | LONRF3 | Human | arsenite(3-) | increases methylation | EXP | | 6480464 | arsenite results in increased methylation of LONRF3 promoter | CTD | PMID:23974009 | LONRF3 | Human | benzo[a]pyrene | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of LONRF3 mRNA | CTD | PMID:19770486 | LONRF3 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of LONRF3 exon and Benzo(a)pyrene affects the methylation of LONRF3 promoter | CTD | PMID:27901495 | LONRF3 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of LONRF3 mRNA | CTD | PMID:26238291 | LONRF3 | Human | benzo[b]fluoranthene | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in decreased expression of LONRF3 mRNA | CTD | PMID:26377693 | LONRF3 | Human | bisphenol A | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of LONRF3 mRNA | CTD | PMID:25181051 | LONRF3 | Human | bisphenol A | decreases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of LONRF3 mRNA | CTD | PMID:35192832 | LONRF3 | Human | bisphenol A | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | bisphenol A results in increased expression of LONRF3 mRNA | CTD | PMID:35598803 | LONRF3 | Human | bromobenzene | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | bromobenzene results in increased expression of LONRF3 mRNA | CTD | PMID:32479839 | LONRF3 | Human | buta-1,3-diene | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | 1 and 3-butadiene results in increased expression of LONRF3 mRNA | CTD | PMID:29038090 | LONRF3 | Human | butanal | increases expression | EXP | | 6480464 | butyraldehyde results in increased expression of LONRF3 mRNA | CTD | PMID:26079696 | LONRF3 | Human | carbon nanotube | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Nanotubes and Carbon analog affects the expression of LONRF3 mRNA | CTD | PMID:25554681 | LONRF3 | Human | carbon nanotube | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of LONRF3 mRNA | CTD | PMID:25554681 and PMID:25620056 | LONRF3 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to LONRF3 gene] | CTD | PMID:28238834 | LONRF3 | Human | chloroprene | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Chloroprene results in increased expression of LONRF3 mRNA | CTD | PMID:23125180 | LONRF3 | Human | choline | multiple interactions | ISO | Lonrf3 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of LONRF3 more ... | CTD | PMID:20938992 | LONRF3 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of LONRF3 mRNA | CTD | PMID:27392435 | LONRF3 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of LONRF3 mRNA | CTD | PMID:27392435 | LONRF3 | Human | cocaine | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Cocaine results in increased expression of LONRF3 mRNA | CTD | PMID:27899881 | LONRF3 | Human | copper(II) sulfate | increases expression | EXP | | 6480464 | Copper Sulfate results in increased expression of LONRF3 mRNA | CTD | PMID:19549813 | LONRF3 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of LONRF3 mRNA | CTD | PMID:25562108 | LONRF3 | Human | cyproconazole | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | cyproconazole results in decreased expression of LONRF3 mRNA | CTD | PMID:22334560 | LONRF3 | Human | dibutyl phthalate | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of LONRF3 mRNA | CTD | PMID:21266533 | LONRF3 | Human | dichloroacetic acid | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Dichloroacetic Acid results in decreased expression of LONRF3 mRNA | CTD | PMID:28962523 | LONRF3 | Human | diquat | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Diquat results in increased expression of LONRF3 mRNA | CTD | PMID:36851058 | LONRF3 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA | CTD | PMID:27188386 | LONRF3 | Human | endosulfan | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Endosulfan results in increased expression of LONRF3 mRNA | CTD | PMID:29391264 | LONRF3 | Human | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of LONRF3 mRNA | CTD | PMID:27188386 | LONRF3 | Human | epoxiconazole | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of LONRF3 mRNA | CTD | PMID:22334560 more ... | LONRF3 | Human | ethanol | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Ethanol results in increased expression of LONRF3 mRNA | CTD | PMID:30319688 | LONRF3 | Human | ethanol | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Ethanol affects the expression of LONRF3 mRNA | CTD | PMID:30319688 | LONRF3 | Human | flutamide | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Flutamide results in increased expression of LONRF3 mRNA | CTD | PMID:24793618 | LONRF3 | Human | folic acid | multiple interactions | ISO | Lonrf3 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of LONRF3 more ... | CTD | PMID:20938992 | LONRF3 | Human | furan | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | furan results in increased expression of LONRF3 mRNA | CTD | PMID:24183702 | LONRF3 | Human | furan | decreases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | furan results in decreased expression of LONRF3 mRNA | CTD | PMID:26194646 | LONRF3 | Human | gentamycin | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of LONRF3 mRNA | CTD | PMID:33387578 | LONRF3 | Human | graphene oxide | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | graphene oxide analog results in decreased expression of LONRF3 mRNA | CTD | PMID:33227293 | LONRF3 | Human | Indeno[1,2,3-cd]pyrene | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | indeno(1 more ... | CTD | PMID:26377693 | LONRF3 | Human | isoprenaline | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Isoproterenol results in increased expression of LONRF3 mRNA | CTD | PMID:20003209 | LONRF3 | Human | L-methionine | multiple interactions | ISO | Lonrf3 (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of LONRF3 more ... | CTD | PMID:20938992 | LONRF3 | Human | lead diacetate | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | lead acetate results in increased expression of LONRF3 mRNA | CTD | PMID:25270620 | LONRF3 | Human | leflunomide | increases expression | EXP | | 6480464 | leflunomide results in increased expression of LONRF3 mRNA | CTD | PMID:28988120 | LONRF3 | Human | mercury dichloride | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Mercuric Chloride results in increased expression of LONRF3 mRNA | CTD | PMID:16507785 | LONRF3 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of LONRF3 mRNA | CTD | PMID:28001369 | LONRF3 | Human | ozone | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Ozone results in increased expression of LONRF3 mRNA | CTD | PMID:25658374 | LONRF3 | Human | ozone | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Ozone results in increased expression of LONRF3 mRNA | CTD | PMID:28623178 and PMID:31397875 | LONRF3 | Human | ozone | multiple interactions | ISO | Lonrf3 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of LONRF3 mRNA more ... | CTD | PMID:25658374 more ... | LONRF3 | Human | p-chloromercuribenzoic acid | increases expression | EXP | | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of LONRF3 mRNA | CTD | PMID:26272509 | LONRF3 | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA | CTD | PMID:27188386 | LONRF3 | Human | paracetamol | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Acetaminophen affects the expression of LONRF3 mRNA | CTD | PMID:17562736 | LONRF3 | Human | parathion | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Parathion results in decreased expression of LONRF3 mRNA | CTD | PMID:34813904 | LONRF3 | Human | perfluorohexanesulfonic acid | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in decreased expression of LONRF3 mRNA | CTD | PMID:37995155 | LONRF3 | Human | perfluorooctanoic acid | multiple interactions | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | [Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of LONRF3 mRNA | CTD | PMID:35163327 | LONRF3 | Human | phenobarbital | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Phenobarbital results in decreased expression of LONRF3 mRNA | CTD | PMID:19270015 | LONRF3 | Human | phenobarbital | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Phenobarbital affects the expression of LONRF3 mRNA | CTD | PMID:23091169 | LONRF3 | Human | phenobarbital | affects expression | EXP | | 6480464 | Phenobarbital affects the expression of LONRF3 mRNA | CTD | PMID:19159669 | LONRF3 | Human | pirinixic acid | multiple interactions | ISO | Lonrf3 (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of LONRF3 mRNA | CTD | PMID:19710929 | LONRF3 | Human | pirinixic acid | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of LONRF3 mRNA | CTD | PMID:23811191 | LONRF3 | Human | propanal | increases expression | EXP | | 6480464 | propionaldehyde results in increased expression of LONRF3 mRNA | CTD | PMID:26079696 | LONRF3 | Human | propiconazole | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | propiconazole results in decreased expression of LONRF3 mRNA | CTD | PMID:22334560 | LONRF3 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of LONRF3 mRNA | CTD | PMID:23557933 | LONRF3 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LONRF3 mRNA | CTD | PMID:27188386 | LONRF3 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of LONRF3 mRNA | CTD | PMID:25895662 | LONRF3 | Human | sodium arsenate | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | sodium arsenate results in increased expression of LONRF3 mRNA | CTD | PMID:21795629 | LONRF3 | Human | sodium arsenite | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of LONRF3 mRNA | CTD | PMID:37682722 | LONRF3 | Human | sotorasib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LONRF3 mRNA | CTD | PMID:36139627 | LONRF3 | Human | tetrachloromethane | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Carbon Tetrachloride affects the expression of LONRF3 mRNA | CTD | PMID:17484886 | LONRF3 | Human | tetrachloromethane | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of LONRF3 mRNA | CTD | PMID:31919559 | LONRF3 | Human | tetrachloromethane | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in increased expression of LONRF3 mRNA | CTD | PMID:31150632 | LONRF3 | Human | tetrachloromethane | multiple interactions | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of LONRF3 mRNA] | CTD | PMID:31150632 | LONRF3 | Human | thioacetamide | increases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of LONRF3 mRNA | CTD | PMID:34492290 | LONRF3 | Human | trametinib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LONRF3 mRNA | CTD | PMID:36139627 | LONRF3 | Human | trichloroethene | decreases expression | ISO | Lonrf3 (Rattus norvegicus) | 6480464 | Trichloroethylene results in decreased expression of LONRF3 mRNA | CTD | PMID:33387578 | LONRF3 | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of LONRF3 mRNA | CTD | PMID:24935251 | LONRF3 | Human | trimellitic anhydride | decreases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | trimellitic anhydride results in decreased expression of LONRF3 mRNA | CTD | PMID:19042947 | LONRF3 | Human | Triptolide | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | triptolide results in increased expression of LONRF3 mRNA | CTD | PMID:32835833 | LONRF3 | Human | triptonide | increases expression | ISO | Lonrf3 (Mus musculus) | 6480464 | triptonide results in increased expression of LONRF3 mRNA | CTD | PMID:33045310 | LONRF3 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of LONRF3 mRNA | CTD | PMID:29154799 | LONRF3 | Human | valproic acid | affects expression | ISO | Lonrf3 (Mus musculus) | 6480464 | Valproic Acid affects the expression of LONRF3 mRNA | CTD | PMID:17963808 | LONRF3 | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of LONRF3 gene | CTD | PMID:29154799 | LONRF3 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of LONRF3 mRNA | CTD | PMID:23179753 more ... | LONRF3 | Human | vorinostat | increases expression | EXP | | 6480464 | vorinostat results in increased expression of LONRF3 mRNA | CTD | PMID:27188386 | |